Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
Looking for a new and suddenly popular business model?
Another transpacific biotech has launched with the backing of an emerging group of venture investors in China as well as a plan to build a pipeline of cancer drugs that can be swiftly developed for the booming Asian market. Not surprisingly, they’re getting started by focusing on drug combinations using red-hot checkpoint therapies to amp up responses for targeted therapies.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters